All In Biotech

Drug Trial Radar · NCT06788912

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 20, 2025

Primary completion

Feb 6, 2032

Study completion Feb 6, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.

Conditions

  • Lung Neoplasm Malignant

Interventions

  • Pembrolizumab (neoadjuvant)Biological

    Before surgery neoadjuvant Pembrolizumab 200 mg by intravenous (IV) infusion on day 1 of each 21-day cycle for 4 cycles

  • CisplatinDrug

    Cisplatin 75 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles

  • GemcitabineDrug

    In squamous tumors Gemcitabine 1000 mg/m\^2 by IV infusion on day 1 and day 8 of each 21-day cycle for 4 cycles.

  • PemetrexedDrug

    In nonsquamous tumors Pemetrexed 500 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles

  • Sacituzumab tirumotecanDrug

    Sacituzumab tirumotecan 4 mg/kg by IV infusion on day 1 of each 14-day cycle for up to 6 cycles

  • H1 receptor antagonistDrug

    Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label

  • H2 receptor antagonistDrug

    Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label

  • Acetaminophen (or equivalent)Drug

    Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label

  • Dexamethasone (or equivalent)Drug

    Administered as rescue medication 8 -10 mg before Sacituzumab tirumotecan infusion per approved product label

  • CarboplatinDrug

    AUC 5 mg/mL min or AUC 6 mg/mL min by IV infusion on day 1 of each 21-day cycle for 4 cycles

  • Pembrolizumab (adjuvant)Biological

    After surgery adjuvant Pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for 13 cycles

  • PaclitaxelDrug

    Paclitaxel 175 or 200 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles.

  • Steroid mouthwash (dexamethasone or equivalent)Drug

    Administered orally as rescue medication 2-5 mL 4 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR)Time frame: Up to approximately 20 weeks
  2. Percent Residual Viable Tumor (%RVT)Time frame: Up to approximately 20 weeks

Locations

39 sites in 9 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center (SCC) ( Site 8004)

    Daphne, Alabama

  • Sansum Clinic (Ridley Tree) ( Site 8012)

    Santa Barbara, California

  • Rocky Mountain Cancer Centers (RMCC) ( Site 8011)

    Lone Tree, Colorado

  • Greenebaum Comprehensive Cancer Center ( Site 0402)

    Baltimore, Maryland

  • MedStar Franklin Square Medical Center ( Site 0033)

    Baltimore, Maryland

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006)

    Eugene, Oregon

  • Texas Oncology - Central/South Texas ( Site 8009)

    Austin, Texas

  • Texas Oncology - Northeast Texas ( Site 8005)

    Tyler, Texas

  • Virginia Cancer Specialists (VCS) ( Site 8002)

    Fairfax, Virginia

  • Centro de Estudios Clínicos SAGA ( Site 0162)

    Santiago, Region M. de Santiago, Chile

  • Fundación Arturo López Pérez ( Site 0161)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0160)

    Santiago, Region M. de Santiago, Chile

  • Alexandra General Hospital of Athens Oncology-Hematology Unit ( Site 0203)

    Athens, Attica, Greece

  • ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 0202)

    Athens, Attica, Greece

  • Metropolitan Hospital-4th Oncology Dept ( Site 0201)

    Athens, Attica, Greece

  • University General Hospital of Heraklion ( Site 0200)

    Heraklion, Irakleio, Greece

  • Országos Korányi Pulmonológiai Intézet ( Site 0060)

    Budapest, Hungary

  • Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 0062)

    Győr, Győr-Moson-Sopron, Hungary

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0061)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Ospedale San Raffaele. ( Site 0171)

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)

    Roma, Italy

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)

    Florence, Tuscany, Italy

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153)

    Poznan, Greater Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151)

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital Clinic de Barcelona ( Site 0092)

    Barcelona, Spain

  • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0702)

    Adana, Turkey (Türkiye)

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 0700)

    Ankara, Turkey (Türkiye)

  • Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 0704)

    Antalya, Turkey (Türkiye)

  • İzmir Suat Seren Chest Disease Training & Research Hospital ( Site 0701)

    Izmir, Turkey (Türkiye)

  • Ondokuz Mayıs Universitesi-Oncology department ( Site 0706)

    Samsun, Turkey (Türkiye)

  • Shalimov Institute of Surgery and Transplantation ( Site 0138)

    Kyiv, Ukraine

  • CNE CC of Oncology Hematol ( Site 0130)

    Cherkasy, Cherkasy Oblast, Ukraine

  • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 0139)

    Chernivtsi, Chernivetska Oblast, Ukraine

  • CNCE Precarpathian Clinical Oncologic Center ( Site 0131)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

  • MNPE LTMU Multidisc. Clin. Hosp. of Emerg. and Intens. Care ( Site 0132)

    Lviv, Lviv Oblast, Ukraine

  • ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0460)

    Rivne, Rivne Oblast, Ukraine

  • Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 0135)

    Vinnytsia, Vinnytsia Oblast, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.